Glenn Gregory M

About Glenn Gregory M

Dr. Gregory M. Glenn is a scientific and medical executive in the vaccine industry, best known for his long tenure at Novavax, a U.S.-listed biotechnology company. He joined Novavax in July 2010 as Senior Vice President, Chief Scientific Officer, was named Senior Vice President, Chief Medical Officer in January 2011, became Senior Vice President, Research and Development in January 2014, and was later promoted to President, Research and Development in March 2016. He remained in that role until his retirement effective March 31, 2023. Novavax then said it would retain him as Strategic Research & Development Advisor, allowing him to continue supporting the company in a consulting capacity after retirement. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1000694/000110465921053246/tm212692d1_pre14a.htm)) Before joining Novavax, Dr. Glenn was the Chief Scientific Officer and founder of Iomai Corporation, which was acquired by Intercell in 2008. His vaccine career began at the Walter Reed Army Institute of Research, where he built early experience in immunology and infectious-disease research. Novavax’s own biographical materials describe him as having more than 20 years of translational vaccine-development experience across viral, bacterial, and parasitic vaccines, and as the author of more than 65 peer-reviewed publications. ([fiercebiotech.com](https://www.fiercebiotech.com/biotech/novavax-announces-management-promotions-to-support-expanded-clinical-activity-2014)) At Novavax, Glenn was a key scientific leader during a period of major operational and clinical expansion. He helped guide the company’s recombinant vaccine programs and its nanoparticle-based platform, including the Matrix-M adjuvant and the COVID-19 vaccine candidate NVX-CoV2373. In 2020, Novavax highlighted him as a panelist discussing COVID-19 vaccine development, underscoring his leadership in the company’s research agenda. His professional reputation is tied to vaccine program design, clinical development strategy, and translating research into late-stage development milestones. ([ir.novavax.com](https://ir.novavax.com/press-releases/2020-06-08-Novavax-President-of-R-D-Dr-Gregory-Glenn-to-Discuss-the-Development-of-COVID-19-Vaccines-on-Panel-at-2020-BIO-Digital))